Company intelligence / Profile preview

Planatome

Phoenix, Arizona, United States

Ownership: Private
Development stage: Other

Overview

Clinical studies show Planatome blades reduce hypertrophic scarring by 86% in facelifts, and accelerate wound healing with less inflammation and scarring, especially notable in diabetics and immunocompromised patient populations

Therapeutic areas: ImmunologyOtherDermatology
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

In licensing talks with leading OEMs; not yet publicized

Beyond the preview

Go deeper on Planatome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Planatome.

Explore the full profile